These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 36352205)

  • 1. Teclistamab: First Approval.
    Kang C
    Drugs; 2022 Nov; 82(16):1613-1619. PubMed ID: 36352205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma.
    Granger K; Gaffney KJ; Davis JA
    J Oncol Pharm Pract; 2023 Apr; 29(3):722-726. PubMed ID: 36775940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
    Usmani SZ; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Rosinol L; Chari A; Bhutani M; Karlin L; Benboubker L; Pei L; Verona R; Girgis S; Stephenson T; Elsayed Y; Infante J; Goldberg JD; Banerjee A; Mateos MV; Krishnan A
    Lancet; 2021 Aug; 398(10301):665-674. PubMed ID: 34388396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA Approval Summary: Teclistamab - A Bispecific CD3 T-cell Engager for Patients with Relapsed or Refractory Multiple Myeloma.
    Baines AC; Kanapuru B; Zhao J; Price LSL; Zheng N; Konicki R; Manning ML; Gehrke BJ; Theoret MR; Gormley NJ
    Clin Cancer Res; 2024 Oct; ():. PubMed ID: 39412823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Teclistamab in Relapsed or Refractory Multiple Myeloma.
    Moreau P; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Nooka AK; Martin T; Rosinol L; Chari A; Karlin L; Benboubker L; Mateos MV; Bahlis N; Popat R; Besemer B; Martínez-López J; Sidana S; Delforge M; Pei L; Trancucci D; Verona R; Girgis S; Lin SXW; Olyslager Y; Jaffe M; Uhlar C; Stephenson T; Van Rampelbergh R; Banerjee A; Goldberg JD; Kobos R; Krishnan A; Usmani SZ
    N Engl J Med; 2022 Aug; 387(6):495-505. PubMed ID: 35661166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teclistamab-cqyv in multiple myeloma.
    Martino EA; Bruzzese A; Labanca C; Mendicino F; Lucia E; Olivito V; Neri A; Morabito F; Vigna E; Gentile M
    Eur J Haematol; 2024 Mar; 112(3):320-327. PubMed ID: 37848191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1.
    Miao X; Wu LS; Lin SXW; Xu Y; Chen Y; Iwaki Y; Kobos R; Stephenson T; Kemmerer K; Uhlar CM; Banerjee A; Goldberg JD; Trancucci D; Apte A; Verona R; Pei L; Desai R; Hickey K; Su Y; Ouellet D; Samtani MN; Guo Y; Garfall AL; Krishnan A; Usmani SZ; Zhou H; Girgis S
    Target Oncol; 2023 Sep; 18(5):667-684. PubMed ID: 37713090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Teclistamab: Mechanism of action, clinical, and translational science.
    Guo Y; Quijano Cardé NA; Kang L; Verona R; Banerjee A; Kobos R; Chastain K; Uhlar C; Pillarisetti K; Doyle M; Smit J; Haddish-Berhane N; Ouellet D
    Clin Transl Sci; 2024 Jan; 17(1):e13717. PubMed ID: 38266057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elranatamab: First Approval.
    Dhillon S
    Drugs; 2023 Nov; 83(17):1621-1627. PubMed ID: 37924427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study.
    Nooka AK; Rodriguez C; Mateos MV; Manier S; Chastain K; Banerjee A; Kobos R; Qi K; Verona R; Doyle M; Martin TG; van de Donk NWCJ
    Cancer; 2024 Mar; 130(6):886-900. PubMed ID: 37960969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience.
    Dima D; Davis JA; Ahmed N; Jia X; Sannareddy A; Shaikh H; Shune L; Kaur G; Khouri J; Afrough A; Strouse C; Lochner J; Mahmoudjafari Z; Raza S; Valent J; Anderson LD; Anwer F; Abdallah AO; Hashmi H
    Transplant Cell Ther; 2024 Mar; 30(3):308.e1-308.e13. PubMed ID: 38151105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study.
    Cortes-Selva D; Perova T; Skerget S; Vishwamitra D; Stein S; Boominathan R; Lau O; Calara-Nielsen K; Davis C; Patel J; Banerjee A; Stephenson T; Uhlar C; Kobos R; Goldberg J; Pei L; Trancucci D; Girgis S; Wang Lin SX; Wu LS; Moreau P; Usmani SZ; Bahlis NJ; van de Donk NWCJ; Verona RI
    Blood; 2024 Aug; 144(6):615-628. PubMed ID: 38657201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
    Anderson LD; Dhakal B; Jain T; Oluwole OO; Shah GL; Sidana S; Perales MA; Pasquini MC
    Transplant Cell Ther; 2024 Jan; 30(1):17-37. PubMed ID: 37913909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daratumumab: First Global Approval.
    McKeage K
    Drugs; 2016 Feb; 76(2):275-81. PubMed ID: 26729183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma.
    Martin TG; Mateos MV; Nooka A; Banerjee A; Kobos R; Pei L; Qi M; Verona R; Doyle M; Smit J; Sun W; Trancucci D; Uhlar C; van de Donk NWCJ; Rodriguez C
    Cancer; 2023 Jul; 129(13):2035-2046. PubMed ID: 36991547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma.
    Pillarisetti K; Powers G; Luistro L; Babich A; Baldwin E; Li Y; Zhang X; Mendonça M; Majewski N; Nanjunda R; Chin D; Packman K; Elsayed Y; Attar R; Gaudet F
    Blood Adv; 2020 Sep; 4(18):4538-4549. PubMed ID: 32956453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrating Immune Therapies for the Treatment of Multiple Myeloma.
    Mikkilineni L; Sidana S
    J Natl Compr Canc Netw; 2023 Dec; 21(12):1303-1311. PubMed ID: 38081142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas.
    Martens AWJ; Rietveld JM; de Boer R; Peters FS; Ngo A; van Mil LWHG; de Heer K; Spaargaren M; Verkleij CPM; van de Donk NWCJ; Adams HC; Eldering E; van Noesel CJM; Verona R; Kater AP
    Cancer Res Commun; 2022 May; 2(5):330-341. PubMed ID: 36875718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The emerging therapeutic landscape of relapsed/refractory multiple myeloma.
    Tanenbaum B; Miett T; Patel SA
    Ann Hematol; 2023 Jan; 102(1):1-11. PubMed ID: 36462062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.